ORTHOPEDIATRICS CORP

KIDS

Held by 2 specialist biotech funds

Share on X

Fund Holdings

RA Capital Management Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 109,959Value: $2.0M

# Signal Note: RA Capital Initiates ORTHOPEDIATRICS (KIDS) RA Capital's entry into KIDS suggests conviction in the pediatric orthopedic device market, where the company holds a dominant position in trauma and sports medicine implants with limited competition. The $2.0M position (modest in absolute terms) indicates a measured conviction level, likely reflecting either early-stage pipeline visibility or attractive valuation rather than an imminent catalyst. No major near-term catalysts are publicly evident, suggesting RA is positioning for medium-term margin expansion or M&A activity in the fragmented pediatric orthopedic space.

Deerfield ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SION2 funds SPRY2 funds TSHA2 funds INSP2 funds BCRX2 funds NUVL2 funds MNPR2 funds SYRE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Deerfield Entry into OrthoPediatrics (KIDS) Deerfield's $2.6M initiation in KIDS suggests conviction in the pediatric orthopedic device company's growth trajectory, likely tied to its flagship products (lateral-entry intramedullary nailing systems, growth-guidance systems) gaining market share in a fragmented $2.8B+ pediatric ortho market. The timing may reflect confidence in recent FDA clearances, reimbursement expansion, or upcoming surgical volume recovery post-pandemic. As a healthcare multi-strategy fund, Deerfield's entry is notable but modest in absolute terms—worth monitoring for institutional validation rather than as a major inflection point.